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Abstract
Background: Elevated serum concentrations of M2-pyruvate kinase (M2-PK) correlate with poor
prognosis in patients with pancreaticobiliary and duodenal cancer, but the expression of M2-PK in
formalin-fixed pancreatic tissue is unknown. We aimed to characterise the immunohistochemical
expression of M2-PK in archived specimens of pancreaticobiliary and duodenal cancers,
premalignant lesions, chronic pancreatitis, and normal pancreas.
Methods: Immunohistochemical staining was performed with mouse anti-M2-PK monoclonal
antibody (clone DF-4) at an optimal dilution of 1:25 on tissue microarrays constructed from
formalin-fixed paraffin-embedded pancreatic tissue of 126 consecutive patients undergoing
pancreatic resections between June 2001 and June 2006. 104 underwent resection for cancer and
22 for chronic pancreatitis. 78 specimens of chronic pancreatitis tissue were obtained adjacent to
areas of cancer. Normal pancreatic tissue was obtained from the resection specimens in a total of
30 patients. Metastatic tumours in 61 regional lymph nodes from 61 patients were also studied. A
further 11 premalignant pancreaticobiliary and duodenal lesions were studied. M2-PK expression
was quantified with the immunohistochemical score (IHS; Range 0-12).
Results: Benign non-ductal tissue in chronic pancreatitis and normal pancreas showed variable
expression of M2-PK (IHS = 1 in 25%, IHS = 2-3 in 40%, IHS>3 in 40%). Benign pancreatic ductal
epithelium, all primary pancreaticobiliary and duodenal premalignant lesions and cancers (and
lymph node metastasis) showed complete lack of expression (IHS = 0).
Conclusion:  Complete lack of M2-PK expression was observed in benign pancreatic ducts,
premalignant lesions and cancer. M2-PK is present only in benign non-ductal epithelium in normal
pancreas and peri-tumoural tissue.
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Background
The enzyme pyruvate kinase (PK) plays a central role in
aerobic glycolysis, a metabolic process that is increased in
tumour cells [1]. During carcinogenesis, the expression of
tissue specific pyruvate kinases, such as M1-PK (muscle
and brain), L-PK (liver and kidney), and R-PK (red blood
cells) is altered and, in addition, the M2-PK isoform, nor-
mally found in embryonic tissue, is also expressed [2,3].
Pyruvate kinase isoenzymes normally exist as highly
active tetramers. However, the tetrameric M2-PK can
change to an inactive dimeric form, which is predominant
in tumour cells, and has a low affinity for phosphoe-
nolpyruvate and also interacts with oncoproteins [4]. The
predominance of the inactive dimeric form in tumour
cells leads to an accumulation of all phosphometabolites
preceding pyruvate kinase in the glycolytic pathway, such
as phosphoenolpyruvate, glycerate 3-phosphate, glyceral-
dehyde 3- phosphate, fructose 1,6-bisphosphate, ribose-5
phosphate and 5'-ribose-pyrophosphate. These are then
available as precursors for synthesis of nucleic acids,
amino acids and phospholipids [5,6]. This switch in
metabolism may allow tumour cells to invade areas with
low concentrations of oxygen and glucose. Tumour M2-
PK has been detected in normal fresh colonic epithelium,
but increases greatly in colonic adenocarcinomas, and
plasma concentrations correlate with tumour load in
patients with lung cancer [1,3]. In addition, raised con-
centrations of tumour M2-PK correlate with the ability of
renal carcinoma cells to metastasise [7]. Recently, tumour
M2-PK has been shown to be measurable not only in
plasma, but also in faeces, leading to an interest in its
potential as a metabolic marker for the screening of
patients at increased risk of colorectal and gastric cancer
[8,9].
Elevated serum concentrations of M2-PK have been found
to correlate with poor prognosis in patients with pancrea-
ticobiliary and duodenal cancer [10]. A pilot study by
Mottet et al. [11] has shown moderate presence of M2-PK
in acetone fixed tissue. There are, however, no published
studies on tissue expression of M2-PK in these tumours in
formalin-fixed tissue. We sought to evaluate the immuno-
histochemical expression of M2-PK in premalignant tissue
and cancers of pancreaticobiliary and duodenal origin
and compare this with expression in chronic pancreatitis
and in normal pancreatic tissue.
Methods
Study design and setting
This was an immunohistochemical study on archived for-
malin-fixed pancreatic tissue from all patients who under-
went pancreatic resections between June 2001 and June
2006 at a university teaching hospital.
Patients
We studied 126 consecutive patients who underwent pan-
creatic resections for malignant and benign disease. A fur-
ther 11 patients who underwent biopsies or resections for
premalignant lesions of pancreaticobiliary and duodenal
origin were also studied. Specimens of chronic pancreati-
tis tissue were obtained from those who underwent resec-
tion for chronic pancreatitis and from areas of chronic
pancreatitis that were adjacent to cancers. Normal pancre-
atic tissue was obtained from the resection specimens,
adjacent to areas of cancer or chronic pancreatitis. Meta-
static lymph nodes from patients with cancer were also
studied.
Construction of tissue microarrays
Formalin-fixed paraffin-embedded tissue blocks contain-
ing pancreatic ductal adenocarcinoma, ampullary adeno-
carcinoma, cholangiocarcinoma, duodenal
adenocarcinoma, chronic pancreatitis and normal pancre-
atic tissue were identified on hematoxylin and eosin
stained slides and marked by a single gastrointestinal his-
topathologist (AMZ). The marked areas in the corre-
sponding paraffin blocks (donor blocks) were used for the
construction of tissue microarrays. From these defined
areas of each specimen, triplicate tissue cores with a diam-
eter of 0.6 mm were taken from donor block and arrayed
into a recipient paraffin block using a tissue puncher/
arrayer (Beecher Instruments, Silver Spring, MD, USA) as
previously described [12]. It has been shown that tissue
microarray cores in triplicate provide a sufficient level of
sampling to give an excellent representation of any block
[13,14]. 5 μm sections of the tissue array block were cut
and placed on Fisherbrand Colorfrost/Plus microscope
slides (Fisher Scientific, Pittsburgh, PA) for immunohisto-
chemical staining.
Immunohistochemical staining
Slides were deparaffinised in xylene, then hydrated via
graded dilutions of alcohol followed by running tap
water. Following a rinse in deionized water, the sections
were incubated with Proteinase-K (S3020; Dako UK Ltd.,
Ely, UK) for 15 min at room temperature to unmask anti-
genicity, and subsequently a Labelled Streptavidin Biotin
(LSAB) immunoperoxidase procedure was performed
using 3,3'-diaminobenzidine (DAB) as the chromogen on
a TechMate 500+ automated stainer (Dako). The staining
protocol consisted of incubating the sections with 0.3%
hydrogen peroxide for 10 min to block endogenous per-
oxidases, washing in phosphate buffered saline (PBS)
buffer, followed by incubation in normal goat serum for
20 minutes. The slides were washed then incubated in
mouse anti-M2-PK monoclonal antibody, (clone DF-4)
from ScheBo® Biotech (Giessen, Germany) at an optimal
dilution of 1:25 (optimisation was achieved using a rangeBMC Cancer 2009, 9:327 http://www.biomedcentral.com/1471-2407/9/327
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of dilutions from 1:10 to 1:50) in a standard antibody
diluent (S2022; Dako, UK) for 1 hr at room temperature,
followed by further washing in Phosphate Buffer Saline
(PBS). Sections were then incubated with a biotin linked
secondary antibody (30 min) followed by washing in PBS
and streptavidin-horseradish peroxidase (30 min) using
reagents in a kit from Dako (K5001). Immunostaining
was visualized using DAB for 10 minutes, also present in
this kit followed by light counterstaining with haematox-
ylin. Two types of negative control experiments were per-
formed on the same TMAs omitting the incubation with
the primary (anti-M2-PK) antibody and the Proteinase K
antigen extraction steps. The TMAs did not stain positively
in either negative control experiment, confirming the pos-
itive staining observed using this protocol was that of M2-
PK. Adenocarcinoma of the lung was used as a positive
control (Figure 1, top panel) and pancreatic islets as neg-
ative controls. Whole tissue sections of pancreatic
tumours (n = 5) were also stained by this protocol.
Immunohistochemical scoring
Immunostaining was reviewed by AMZ and AMM inde-
pendently and the average score taken. There was no inter-
observer variability (i.e. 100% concurrence) for negative
staining. However, for positive staining the inter-observer
variability was 2.9%. The level of M2-PK expression was
calculated by combining an estimate of the percentage of
immunoreactive cells (quantity score) with an estimate of
the staining intensity (staining intensity score) as follows.
No staining was scored as 0, 1-10% of cells with positive
staining were scored as 1, 10-50% as 2, 50-70% as 3, and
70-100% as 4. Staining intensity was rated on a scale of 0
to 3 as follows: 0 = negative (no colour); 1 = weak brown,
2 = moderate brown, and 3 = strong brown. The raw data
were converted to the immunohistochemical score (IHS)
by multiplying the quantity and staining intensity scores.
Therefore, the score could range from 0 to 12 [15].
Ethics
The conduct of this study was approved by the Ethics
Committee of Nottingham University Hospitals.
Results
The median (IQR) age of the 77 male and 49 female
patients was 63 (56-71) years. Of the 126 consecutive
patients who underwent pancreatic resections 104 had
histologically confirmed pancreaticobiliary and duodenal
cancer and 22 had chronic pancreatitis. Specimens of
chronic pancreatitis tissue were obtained from areas adja-
cent the cancer in a further 78 patients. Normal pancreatic
tissue was obtained from the resection specimens, adja-
cent to areas of cancer or chronic pancreatitis in a total of
30 patients. Sixty one metastatic lymph nodes from 61
patients were also studied. The premalignant lesions stud-
ied were pancreatic intraepithelial neoplasia-I (Pan IN-I)
(n = 1), Pan IN-III (n = 1), ampullary adenoma with low
Strong expression of M2-pyruvate kinase in a positive control  (lung cancer) and benign pancreatic non-ductal epithelium Figure 1
Strong expression of M2-pyruvate kinase in a positive 
control (lung cancer) and benign pancreatic non-duc-
tal epithelium: Immunohistochemical staining for M2-pyru-
vate kinase on formalin fixed lung adenocarcinoma (× 20), 
demonstrating a strong uptake of the stain. This was used as 
a positive control (top panel); Immunohistochemical staining 
for M2-pyruvate kinase on chronic pancreatitis (× 20), dem-
onstrating moderate staining of benign non-ductal pancreatic 
epithelium (middle panel); Immunohistochemical staining for 
M2-pyruvate kinase on normal non-ductal pancreatic epithe-
lium (× 20), demonstrating a strong uptake of stain (bottom 
panel).BMC Cancer 2009, 9:327 http://www.biomedcentral.com/1471-2407/9/327
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grade dysplasia (n = 2), ampullary adenoma with high
grade dysplasia (n = 2), ampullary intraductal low grade
dysplasia (n = 1), pancreatic intraductal low grade dyspla-
sia (n = 1), common bile duct with low grade dysplasia (n
= 1), common bile duct with low grade tubular adenoma
(n = 1), duodenal tubular adenoma with high grade dys-
plasia (n = 1).
The degree of differentiation of various cancers and lymph
node involvement are described in Table 1. The immuno-
histochemical scores of the stained tissue are shown in
Tables 2 and 3. There was consistent lack of expression of
M2-PK (IHS = 0) in all pancreaticobiliary and duodenal
tumours, irrespective of tumour type or differentiation
(Figure 2a-c). Similarly, metastatic pancreaticobiliary and
duodenal tumours in regional lymph nodes lacked the
expression of M2-PK (Figure 2d). However, chronic pan-
creatitis tissue and normal pancreatic tissue around these
tumours were found to have a variable cytoplasmic
expression (IHS = 1-12) of M2-PK in non-ductal tissue,
but benign ductal epithelium lacked complete expression
(Figure 1 middle and bottom panel). All premalignant
lesions of pancreaticobiliary and duodenal origin also
showed complete lack of expression of M2-PK (Figure 3).
The staining pattern seen in the tissue microarrays was
similar to that seen in whole tissue sections.
Discussion
M2-PK is thought to be a serum marker for a variety of
cancers [10,16-23] and its serum concentrations in
patients with pancreatic cancer correlate with disease bur-
den and prognosis [10]. Furthermore, a previous study
showed serum M2-PK levels to be elevated not only in
pancreatic cancer but also in benign pancreatic disease
[24], suggesting a more complex mechanism of expres-
sion. Since the tissue expression of M2-PK in pancreatico-
biliary and duodenal cancers was previously unknown,
we sought to examine this using immunohistochemistry.
Quite unexpectedly, we found complete lack of expres-
sion of M2-PK in every case of pancreaticobiliary and duo-
Lack of expression of M2-pyruvate kinase in duct-derived cancers Figure 2
Lack of expression of M2-pyruvate kinase in duct-derived cancers: (a) Immunohistochemical staining for M2-pyruvate 
kinase on diffuse anaplastic pancreatic ductal adenocarcinoma (× 20), demonstrating a complete lack of staining in tumour epi-
thelium; (b) Immunohistochemical staining for M2-pyruvate kinase on poorly differentiated pancreatic ductal adenocarcinoma, 
with adjacent chronic pancreatitis (× 20), demonstrating a complete lack of staining in the tumour, but intense staining in the 
benign non-ductal reactive epithelium; (c) Immunohistochemical staining for M2-pyruvate kinase on well differentiated adeno-
carcinoma pancreas (× 20); (d) Immunohistochemical staining for M2-pyruvate kinase on metastatic pancreatic ductal adeno-
carcinoma in the regional lymph node (× 20), demonstrating a complete lack of staining in the tumour epithelium and lymph 
node.BMC Cancer 2009, 9:327 http://www.biomedcentral.com/1471-2407/9/327
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denal cancer examined irrespective of type and
differentiation. In contrast, varying degrees of expression
of M2-PK were observed in all normal non-ductal pancre-
atic tissue and chronic pancreatitis, but benign pancreatic
ducts lacked expression. All premalignant lesions of pan-
creaticobiliary and duodenal origin also showed complete
lack of expression of M2-PK. It appears that although pan-
creatic acinar tissue expresses M2-PK, the lack of M2-PK
expression is a common immunohistochemical feature of
normal pancreatic ductal epithelium and of dysplastic or
neoplastic change in pancreaticobiliary and duodenal tis-
sue, which, to the best of our knowledge, has not been
reported previously.
The lack of staining observed in our study could have been
due to undersampling, as we only examined TMA cores.
However, this is unlikely as previous studies [13,14] have
shown that three cores are adequate. Moreover, whole tis-
sue sections of pancreatic tumours stained identically to
the tissue microarrays also demonstrated lack of M2-PK in
pancreatic cancer and benign ductal epithelium. Another
reason could be that the antibody epitope that we used
may only be staining the active (tetrameric) form of pyru-
vate kinase, in which case the positive control (lung aden-
ocarcinoma) used in this study should not have stained.
Concurrent plasma concentrations of M2-PK could not be
evaluated in our series as the study had a retrospective
design.
The differential staining observed between benign pancre-
atic ducts, premalignant ductal lesions, duct-derived can-
cers and non-ductal epithelium may possibly reflect an
altered Warburg effect in the pancreatic ducts (alteration
of aerobic glycolysis by which ductal cells survive in
hypoxic conditions and produce lactate) and it is quite
possible that alternative pathways of pancreatic tumour
cell survival may exist which are yet to be unravelled [25].
Such an alteration of aerobic glycolysis in ducts and duct
derived cancers may possibly explain their resilience to
hypoxia and therefore a survival advantage of cancer cells
in metabolically hostile microenvironments.
The antibody that we used was designed only for forma-
lin/acetone fixed pancreatic specimens and not for fresh
pancreatic tissue. Our study contrasts with the pilot study
by Mottet et al. [11], in that their method of antigen
retrieval is not clearly explained and they used the same
antibody in acetone fixed pancreatic tissue. However, as
yet, these data [11] have only been published in abstract
form and further details are awaited. Artifactual immu-
nostaining in acetone fixed tissue is well known phenom-
enon as the fixation occurs through a process of
denaturation, by the disruption of hydrophobic bonds
which give protein their tertiary structure [26]. The precip-
itation and aggregation of proteins observed through ace-
Lack of expression of M2-pyruvate kinase in premalignant  pancreaticobiliary epithelium Figure 3
Lack of expression of M2-pyruvate kinase in prema-
lignant pancreaticobiliary epithelium: Premalignant 
lesions showing lack of M2-PK expression pancreatic intraep-
ithelial neoplasia I (× 20) (top panel); pancreatic intraepithe-
lial neoplasia III (× 20) (middle panel); common bile duct with 
low-grade dysplasia (× 20) (bottom panel).BMC Cancer 2009, 9:327 http://www.biomedcentral.com/1471-2407/9/327
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Table 1: Tumour type and differentiation for the 104 pancreatic resections for cancer
Pancreatic ductal 
adenocarcinoma
(n = 44)
Ampullary 
adenocarcinoma
(n = 31)
Cholangiocarcinoma
(n = 24)
Duodenal 
adenocarcinoma
(n = 5)
Well differentiated 5 1 7 0
Moderately differentiated 29 18 17 3
Poorly differentiated 10 5 7 2
Patients with metastatic 
lymph nodes
26 12 20 3
Table 2: Immunohistochemical scoring (IHS) of the expression of M2-PK in malignant and benign pancreatic tissue microarrays.
TISSUE (n) IMMUNOHISTOCHEMICAL SCORE [n (%)]
0 1 2-3 4-5 6-7 8-9 10-12
Pancreatic ductal adenocarcinoma (44) 44 (100)
Tumour in lymph nodes (26) 26 (100)
Chronic pancreatitis (36) 2 (6) 30 (83) 4 (11)
Normal pancreas (8) 7 (87.5) 1(12.5)
Ampullary adenocarcinoma (31) 31 (100)
Tumour in lymph nodes (20) 20 (100)
Chronic pancreatitis (26) 9 (34.6) 6 (23) 7 (27) 4 (15.4) 9 (34.6)
Normal pancreas (8) 2 (25) 4(50) 1 (12.5) 1 (12.5)
Cholangiocarcinoma (24) 24 (100)
Tumour in lymph nodes (12) 12(100)
Chronic pancreatitis (11) 2 (18.1) 5 (45.5) 4 (36.4)
Normal pancreas (11) 5 (45.5) 5 (45.5) 1 (9)
Duodenal adenocarcinoma (5) 5 (100)
Tumour in lymph nodes (3) 3 (100)
Chronic pancreatitis (5) 4 (80) 1 (20)
Normal pancreas (1) 1 (100)
Chronic pancreatitis (22) 12 (54.5) 8 (36.5) 2 (9)
Normal pancreas around pancreatitis (2) 1 (50) 1 (50)
Table 3: Summary of M2-PK expression in benign and malignant pancreatic tissue.
TISSUE (n) IMMUNOHISTOCHEMICAL SCORE [n (%)]
0 1 2-3 4-5 6-7 8-9 10-12
Primary adenocarcinoma (104) 104 (100)
Regional lymph nodes (tumour +ve 61) 61 (100)
Regional lymph nodes (tumour -ve 39) 39 (100)
Chronic pancreatitis (100) 25 (25) 39 (39) 22 (22) 10 (10) 4 (4)
Normal pancreas (30) 12 (40) 9 (30) 6 (20) 2 (7) 1 (3)BMC Cancer 2009, 9:327 http://www.biomedcentral.com/1471-2407/9/327
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tone fixation is a very different process observed from the
cross-linking, which occurs with the aldehyde fixatives.
Formalin fixation is far more reliable method than ace-
tone fixation in preserving the tertiary antigenic structure
of proteins of interest. It is possible that the M2-PK may
have degraded, through the process of acetone fixation, in
their study and the immunostaining observed could have
been a false positive artefact.
Elevated M2-PK concentrations in plasma or serum, are
not specific enough to be a screening tool in pancreatic
cancer as high levels of this enzyme can also be found in
the plasma/serum of patients with pancreatitis and other
inflammatory conditions, unrelated to pancreatic pathol-
ogy [27]. M2-PK may be elevated falsely in patients with
jaundice, which may reflect altered biokinetics of its elim-
ination from blood [28]. Moreover, the source of M2-PK
detected in the serum has not yet been confirmed to date.
Our study may provide a clue that the source may be nor-
mal or inflamed pancreatic non-ductal epithelium.
Hence, tissue expression of M2-PK may reflect more accu-
rately the underlying pancreatic pathology. It would be of
interest to observe if the rare acinar cell pancreatic carci-
noma (non-ductal epithelium derived cancer) expresses
M2-PK and if true, this is likely to be a positive expression
marker for acinar-cell derived tumours.
Conclusion
In this study, positive immunohistochemical staining for
M2-PK was observed only in benign non-ductal epithe-
lium in normal pancreas and peri-tumoural tissue and
there was a complete lack of M2-PK expression in benign
pancreatic ducts, premalignant lesions and cancer. This
finding may help complement the immunohistochemical
diagnosis of pancreaticobiliary and duodenal neoplasms.
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